Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from May 2020.
Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from May 2020.
5. Expert Talks Immunotherapy for Triple Negative Breast Cancer Treatment
The addition of immunotherapy to the triple-negative breast cancer treatment landscape has led to a paradigm shift and sparked an abundance of research with immuno-oncology drugs in new combinations and settings, explained Hope S. Rugo, MD.
4. In Case You Missed It: 5 New FDA Oncology Drug Approvals
The FDA continues to approve new cancer drugs, with multiple treatment regimens getting the agency’s OK within the last week. In case you missed it, here, we share a list of the 5 most recent FDA approvals in the cancer space.
3. Cancer Survivors, Caregivers Say ‘Thank You’ to Oncology Nurses
In conjunction with National Nurses’ Week, readers of Oncology Nursing News’ sister publication, CURE — which is meant for patients, survivors, and caregivers of those with cancer – expressed gratitude for their oncology nurses. In this piece, we shared what some of them had to say.
2. Cellular Therapies Boost Outcomes for Aggressive Lymphomas
While aggressive lymphoma such as mantle cell lymphoma typically end in relapse, precision medicine and cellular therapies are improving outcomes for patients, according to Michael Wang, MD.
1. Not ‘Just a Nurse’
From the bedside to the boardroom, nurses are leaders, practitioners, scientists, and transferors of knowledge. In this piece from our co-editor in chief, Stephanie Jackson, learn more about what makes oncology nurses more than ‘just a nurse’.
Thanks for reading!
FDA Approves T-DXd for Previously Treated HER2-Low and -Ultralow Metastatic Breast Cancer
Published: January 27th 2025 | Updated: January 28th 2025T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in patients whose disease progressed on prior endocrine therapy in the metastatic setting.
ctDNA Status May Be Prognostic for DFS With Celecoxib for Stage III Resected Colon Cancer
January 26th 2025While ctDNA positivity was linked to worse overall disease-free survival (DFS) in stage III resected colon cancer, it was associated with significantly improved DFS with celecoxib compared to placebo.